相关临床试验
589
126 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
进行中（未招募）
17
2.9%
已完成
103
17.5%
Enrolling By Invitation
6
1.0%
尚未招募
103
17.5%
招募中
145
24.6%
暂停
3
0.5%
终止
4
0.7%
Unknown
200
34.0%
撤回
8
1.4%
暂无批准数据
- A global analysis of women aged 55 and older across 204 countries found significant geographic overlap in breast cancer and atrial fibrillation incidence, with highest rates in North America, Europe, and Oceania. - Smoking and alcohol use emerged as shared modifiable risk factors for both conditions, with alcohol being the strongest contributor—linked to up to 12% higher BC incidence and 10% higher AF incidence. - Population-attributable fraction modeling estimated that reducing alcohol and smoking to theoretical minimum-risk levels could cut breast cancer by 29% and atrial fibrillation by nearly 12% globally. - The study, published in the Journal of the American Heart Association, is the first to combine global data with machine learning to map spatial patterns and shared risk factors for these two diseases.
- Dayspring Pharma's Phase II trial of CG2001 foam met its primary endpoint in 110 Chinese men with androgenetic alopecia, demonstrating statistically significant and clinically meaningful results. - The optimal dosing regimen of 5% minoxidil plus 0.075% finasteride twice daily showed approximately 50% efficacy improvement compared to existing Chinese minoxidil foam studies. - CG2001 demonstrated rapid onset of action, surpassing peak efficacy of comparator studies by Week 12, with excellent safety profile and extremely low systemic exposure. - The company plans to advance CG2001 into Phase III development based on the promising efficacy, safety, and rapid onset data from this 30-week study.
- Super Vision Technology's i-NYS implantable device has received market approval from China's NMPA, becoming the world's first approved treatment for congenital nystagmus, a condition previously considered incurable in ophthalmology. - The device uses microcurrent stimulation to regulate extraocular muscle movement and has demonstrated efficacy in multi-center clinical trials involving 71 patients, significantly improving visual function and quality of life. - Congenital nystagmus affects approximately 1.3 million patients in China and 7 million globally, with the condition manifesting between 3-6 months after birth and persisting for life. - The breakthrough represents over 20 years of development by Professor Wang Lejin's team and marks a significant advancement in China's ophthalmology innovation capabilities.
- Leads Biolabs presented Phase I/II data for LBL-034, a GPRC5D/CD3 bispecific antibody, showing an 82.5% overall response rate in relapsed/refractory multiple myeloma patients. - The therapy demonstrated strong efficacy across difficult-to-treat subgroups, including 100% response rate in extramedullary disease patients at the highest dose level. - LBL-034 showed a favorable safety profile with no dose-limiting toxicities up to 1200 μg/kg and predominantly mild adverse events. - The 12-month progression-free survival rate reached 61.2% across dose levels, with median follow-up of 9.6 months indicating durable clinical benefit.
- Gan & Lee Pharmaceuticals has initiated GRADUAL-3, a 24-week phase 3 clinical study evaluating once-monthly bofanglutide injection for weight management in adults with obesity or overweight. - The study represents the first Chinese once-monthly GLP-1 receptor agonist designed to maintain achieved weight loss and improve long-term treatment adherence through reduced injection frequency. - Bofanglutide is part of a comprehensive GRADUAL clinical development program with over 1,000 planned participants across three phase 3 studies, including a head-to-head comparison with semaglutide.
- The B7-H3-targeted antibody-drug conjugate HS-20093 achieved a 20% confirmed overall response rate in osteosarcoma patients and 23.1% in soft tissue sarcoma patients at the 12 mg/kg dose level in the phase 2 ARTEMIS-002 trial. - HS-20093 demonstrated superior efficacy at the higher 12 mg/kg dose compared to 8 mg/kg, with median progression-free survival of 8.4 months for osteosarcoma and 9.4 months for soft tissue sarcoma. - The FDA granted breakthrough therapy designation to HS-20093 for relapsed/refractory osteosarcoma patients who have progressed on two or more prior therapies in January 2025. - The drug showed manageable safety profile with myelosuppression as the primary toxicity, supporting advancement to confirmatory phase 3 studies.
- QL Biopharm's zovaglutide demonstrated 13.8% weight loss at 24 weeks with once-monthly 160 mg dosing in a Phase 2 trial of 303 overweight or obese subjects. - The novel GLP-1 receptor agonist features dual-fatty acid chain modification that enhances albumin binding, enabling the first potential monthly dosing regimen in obesity treatment. - Monthly dosing showed comparable efficacy to biweekly administration but with fewer gastrointestinal adverse events during maintenance therapy. - The company plans to advance zovaglutide into Phase 3 pivotal studies to address the unmet clinical demand for longer-acting obesity treatments.
- Kintor Pharma's KX-826 tincture 1.0% achieved its primary endpoint in a Phase II clinical trial for male androgenetic alopecia treatment. - Both 0.5% and 1.0% twice-daily dosing groups showed statistically significant hair growth improvements compared to placebo after 24 weeks. - The treatment demonstrated satisfactory safety profile with no drug-related sexual dysfunction adverse events reported. - An independent Data Monitoring Committee recommended proceeding to Phase III without modifications to study design or sample size.
- Alebund Pharmaceuticals announced that its investigational drug AP301, a novel fiber-iron-based phosphate binder, met its primary endpoint in a pivotal phase 3 study for controlling serum phosphorus in dialysis patients with hyperphosphatemia. - The 52-week randomized, open-label study enrolled 474 participants across 50 sites in China and demonstrated statistically significant and clinically meaningful improvement in serum phosphorus control compared to sevelamer carbonate. - AP301 offers advantages including high phosphate-binding capability, no need to chew before swallowing, no volume expansion in gastric fluid, and no systemic absorption, potentially addressing the low patient compliance issue where less than 50% of patients achieve good phosphate control. - The company plans to engage with China's NMPA regarding its new drug application in Q3 2025, targeting a market expected to reach 10 billion RMB by 2035.
• HTD1801, a plant-derived berberine medication, demonstrated significant blood glucose control in type 2 diabetes patients, with the highest dose reducing HbA1c by 0.7% over 12 weeks. • The phase 2 trial involving 113 patients showed HTD1801 improved multiple health markers, including glucose metabolism, insulin resistance, and cardiovascular parameters. • The drug was generally well-tolerated, with mostly mild to moderate side effects, positioning it as a potential new oral treatment option for type 2 diabetes management.
